Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail TherapeuticsBusiness Wire • 10 days ago
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Precision BioSciences (NASDAQ:DTIL - Free Report) had its price target boosted by HC Wainwright to $60.00 in a research report sent to investors on Thursday, Benzinga reports. The brokerage currently...
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akebia Therapeutics (AKBA Research Report) and Precision BioSciences...
Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings estimates for Precision BioSciences in a report issued on Thursday, March 28th. HC...
Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) - Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Precision BioSciences in a research report issued to clients and investors...
Precision BioSciences (NASDAQ:DTIL - Get Free Report) had its target price hoisted by analysts at HC Wainwright to $60.00 in a research report issued to clients and investors on Thursday, Benzinga...
Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Precision BioSciences (DTIL Research Report). The associated pric...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits...